Stock Analysis

Toho Holdings Third Quarter 2025 Earnings: EPS: JP¥75.29 (vs JP¥73.15 in 3Q 2024)

TSE:8129
Source: Shutterstock

Toho Holdings (TSE:8129) Third Quarter 2025 Results

Key Financial Results

  • Revenue: JP¥407.1b (up 5.8% from 3Q 2024).
  • Net income: JP¥4.87b (up 3.9% from 3Q 2024).
  • Profit margin: 1.2% (in line with 3Q 2024).
  • EPS: JP¥75.29 (up from JP¥73.15 in 3Q 2024).
earnings-and-revenue-growth
TSE:8129 Earnings and Revenue Growth February 9th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Toho Holdings Earnings Insights

Looking ahead, revenue is forecast to grow 1.1% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Healthcare industry in Japan.

Performance of the Japanese Healthcare industry.

The company's shares are down 4.0% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Toho Holdings has 1 warning sign we think you should be aware of.

Valuation is complex, but we're here to simplify it.

Discover if Toho Holdings might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About TSE:8129

Toho Holdings

Engages in the wholesale distribution of pharmaceutical products in Japan.

Excellent balance sheet and fair value.

Community Narratives

Priced for AI perfection - cracks are emerging
Fair Value US$90.15|44.027% overvalued
ChadWisperer
ChadWisperer
Community Contributor
NVDA Market Outlook
Fair Value US$341.12|61.937% undervalued
NateF
NateF
Community Contributor
Karoon Energy (ASX:KAR) - Buy Baby Buy 🚀
Fair Value AU$5.10|70.294% undervalued
StockMan
StockMan
Community Contributor